Our data illustrate that the inhibition of BRD4 has a robust growth inhibitory effect on GIST cells in vitro, suggesting that secondary imatinib resistance is a result of PI3K/AKT signalling pathway activation. This evidence concerns the gene AKT1 and gastrointestinal stromal tumor.